CTI Clinical Trial and Consulting Services

ProteoGenex is an established, innovative provider of biological specimens and clinical information of the highest quality standards.

We are a privately held US company founded in Los Angeles, CA in 2003. With headquarters in Culver City, CA, we also have a large, state-of-the-art research laboratory in Moscow, Russia.

The ProteoGenex team consists of 35 employees, including 30 Molecular Biologists, Cell Biologists, Biochemists, and Pathologists (15 PhDs, 5 MDs, 15 MSs).

Our biorepository offers an extensive inventory of biospecimens as well as an exclusive, custom-design human tissue-based research service, which is the company’s largest and fastest growing business segment.
Our unique and comprehensive biobank is composed of well-defined and categorized clinical samples, including frozen and FFPE tissues, blood, serum, plasma, bone marrow, tissue microarrays, etc. All ProteoGenex specimens are collected from a vast network of academic and professional clinical institutions under strict regulatory and ethical standards.

We have over 200,000 individual biomaterials covering disease targets in the fields of Oncology, Dermatology, Neurology, Immunology, Infectious Diseases, Autoimmune and Metabolic Disorders, and many more. Our products are derived from a variety of diseased human sources as well as from normal tissues. All specimens are supported by extensive pathology information and patient’s’ clinical history documentation.

Accell Clinical Research is an international full-service Contract Research Organization (CRO) managing Phase I-III clinical trials for 10+ years across Eastern Europe. With local presence, including highly qualified medical staff and legal entities in the region, we successfully recruit patients both in EU and outside EU in post-Soviet countries (CIS). All together we provide guaranteed fast patient recruitment in 20+ countries across the region.

⬇︎ ACCELL'S SERVICES for Phase I-III clinical trials:

• Strategic guidance and trial set-up:
• Feasibility research and site selection
• Study documentation development
• Regulatory support
• Clinical supply import and management
• Selection and management of clinical study vendors
• Project management
• Clinical & medical monitoring
• Data management and biostatistics
• Quality assurance
• Safety management
• TMF/eTMF services
• Functional outsourcing of a clinical team

⬇︎ THERAPEUTIC AREAS
• Oncology
• Cardiovascular
• Immunology
• Gastroenterology
• Neurology
• Endocrinology

Accelsiors is a scientifically-driven, global, full-service Contract Research Organization (CRO). We support the Pharma industry globally to accelerate and manage every activity across clinical drug development.

Since 2002, we have been committed to providing Sponsors working in highly complex disease indications with the scientific knowledge, regulatory expertise and quality operations necessary to achieve their development objectives.

Accelsiors expertise includes studies in the following areas:

• Biosimilars
• Complex Generics
• Hepatology
• Infectious Disease
• Inflammatory Disease
• Nephrology
• Neurology
• Oncology
• Pulmonary
• Rare Diseases
• Rheumatology

We serve a global Customer base, which ranges from emerging biotechnology companies to multi-national pharmaceutical companies.

Accelsiors is committed to establishing meaningful collaborations with our Sponsors and executing studies, regardless of size and scope, with quality being the key driver in all that we do.

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 3,700 highly qualified people. The Company’s 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence.

Pentagrit is a zebrafish discovery lab offering efficacy screening services. Facilities includes state of art zebrafish facility for pre-clinical development across segments Oncology, Inflammation, Gene Therapy, Metabolic and Cardiovascular, Neurology and Infectious diseases.

Zebrafish Gene Therapy Programme
Immunogenicity Optimizer for Vector and Target DNA

Zebrafish Tumor Programme
Diffuse Intrinsic Pontine Glioma
Pancreatic Tumor
(NSCLC) Lung Cancer
Leukemia

Zebrafish Metabolic Programme
Left Ventricular Hypertrophy
Type II Diabetes
Obestity
NASH and NAFLD

Zebrafish Neuronal Programme
Parkinson’s
Alzheimer’s
Multiple Sclerosis

Zebrafish Rare Disease Programme
RETT Syndrome
Batten Disease

Zebrafish Pain Programme
Intestinal Pain
Peripheral Pain

Zebrafish Inflammation Programme
Arthritis
Psoriasis

Zebrafish Infection Programme
Dengue
Malaria
Chikungunya
Sars CoV-2